

CONTENTS

IMPORTANT NOTICE TO PROSPECTIVE [REDACTED]

This document is issued by our Company solely in connection with the [REDACTED] and the [REDACTED] and does not constitute an [REDACTED] to sell or a solicitation of an [REDACTED] to [REDACTED] for or buy any security other than the [REDACTED]. This document may not be used for the purpose of, and does not constitute, an [REDACTED] to sell or a solicitation of an [REDACTED] to [REDACTED] for or [REDACTED] or [REDACTED] in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED] or the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document and the [REDACTED] and sale of the [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdiction pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely only on the information contained in this document to make your [REDACTED] decision. We have not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not included in this document must not be relied on by you as having been authorized by us, the [REDACTED], the [REDACTED], the [REDACTED], the Sole Sponsor, the [REDACTED], any of our or their respective directors, officers, employees, partners, agents or representatives, or any other party involved in the [REDACTED]. Information contained on our website www.bettapharma.com does not form part of this document.

	Page
Expected Timetable	iv
Contents	vi
Summary	1
Definitions	21
Glossary	30
Forward-looking Statements	36
Risk Factors	37
Waivers	59
Information about this Document and the [REDACTED]	61
Directors and Parties Involved in the [REDACTED]	64
Corporate Information	68
Industry Overview	70
Regulatory Overview	95
History, Development and Corporate Structure	116
Business	128
Financial Information	212
Connected Transactions	246
Share Capital	256

CONTENTS

Substantial Shareholders	258
Directors and Senior Management	260
Future Plans and Use of [REDACTED]	271
[REDACTED]	275
Structure of the [REDACTED]	282
How to Apply for [REDACTED]	288
Appendix I Accountants’ Report	I-1
Appendix II Unaudited [REDACTED] Financial Information	II-1
Appendix III Property Valuation Report	III-1
Appendix IV Summary of Articles of Association	IV-1
Appendix V Statutory and General Information	V-1
Appendix VI Documents Delivered to the Registrar of Companies in Hong Kong and Available on Display	VI-1